The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 13, Issue 5, Pages 273-290
Publisher
Springer Nature
Online
2016-03-15
DOI
10.1038/nrclinonc.2016.25
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E -TCL1 CLL mouse model
- (2015) F. McClanahan et al. BLOOD
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers
- (2015) Janos L. Tanyi et al. CANCER RESEARCH
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
- (2015) Hollie J Pegram et al. Immunotherapy
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
- (2015) Sebastian Kobold et al. JNCI-Journal of the National Cancer Institute
- Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
- (2015) Evan J Lipson et al. Journal of Translational Medicine
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
- (2015) D Saulep-Easton et al. LEUKEMIA
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Nurse like cells: chronic lymphocytic leukemia associated macrophages
- (2015) Frédéric Boissard et al. LEUKEMIA & LYMPHOMA
- Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
- (2015) Kevin J Curran et al. MOLECULAR THERAPY
- Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy
- (2015) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming
- (2015) Melanie P. Matheu et al. Nature Communications
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
- (2015) Sebastian Kobold et al. JNCI-Journal of the National Cancer Institute
- IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo
- (2015) Mythili Koneru et al. OncoImmunology
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
- (2014) R. Jitschin et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
- (2014) Dass S. Vinay et al. BMB Reports
- Immune modulation for cancer therapy
- (2014) J Naidoo et al. BRITISH JOURNAL OF CANCER
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- (2014) Shannon L. Maude et al. CANCER JOURNAL
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
- (2014) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Targeting CD137 enhances the efficacy of cetuximab
- (2014) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
- (2014) H J Pegram et al. LEUKEMIA
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma
- (2014) N. Singh et al. Cancer Immunology Research
- Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
- (2014) C. Berger et al. Cancer Immunology Research
- Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
- (2014) S. Kitano et al. Cancer Immunology Research
- Mechanisms of TIGIT-driven immune suppression in cancer
- (2014) Sema Kurtulus et al. Journal for ImmunoTherapy of Cancer
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
- (2013) A. Mardiros et al. BLOOD
- Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
- (2013) Sarah Tettamanti et al. BRITISH JOURNAL OF HAEMATOLOGY
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity
- (2013) C. Ankri et al. JOURNAL OF IMMUNOLOGY
- Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
- (2013) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas
- (2013) Sid P Kerkar et al. MOLECULAR THERAPY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
- (2013) D. A. Schaer et al. Cancer Immunology Research
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
- (2012) H. J. Pegram et al. BLOOD
- ATRA plus arsenic gets another "A" in APL
- (2012) J. H. Park BLOOD
- T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
- (2012) J. C. Riches et al. BLOOD
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signaling pathways in aged T cells – A reflection of T cell differentiation, cell senescence and host environment
- (2012) Jörg J. Goronzy et al. SEMINARS IN IMMUNOLOGY
- CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
- (2012) Rebecca Waitz et al. OncoImmunology
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
- (2012) Andreas A. Hombach et al. OncoImmunology
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL
- (2011) P. Christopoulos et al. BLOOD
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
- (2011) Sid P. Kerkar et al. JOURNAL OF CLINICAL INVESTIGATION
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
- (2011) A. M. Paterson et al. JOURNAL OF IMMUNOLOGY
- Beyond Ipilimumab: New Approaches Target the Immunological Synapse
- (2011) K. Garber JNCI-Journal of the National Cancer Institute
- T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
- (2011) K Mihara et al. LEUKEMIA
- Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
- (2011) Noah S Butler et al. NATURE IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- (2011) Michael A. Curran et al. PLoS One
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
- (2011) B. Burington et al. Science Translational Medicine
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
- (2010) M. Hudecek et al. BLOOD
- Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
- (2010) J. Mitsui et al. CLINICAL CANCER RESEARCH
- OX40 is required for regulatory T cell–mediated control of colitis
- (2010) Thibault Griseri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- (2010) V Hoyos et al. LEUKEMIA
- Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
- (2010) Giovanni D’Arena et al. LEUKEMIA RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
- (2010) Adam D. Cohen et al. PLoS One
- Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
- (2010) V. A. Pedicord et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
- (2010) H.-T. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-
- (2010) M. Kraman et al. SCIENCE
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2
- (2009) T. Okamura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2
- (2008) Bianca Heemskerk et al. HUMAN GENE THERAPY
- First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
- (2008) Andrea Molckovsky et al. Journal of Hematology & Oncology
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started